By Fineline Cube 
French firm Servier Pharmaceutical plc.’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, has been approved for clinical use in Beijing. It is now available for patients with IDH-mutant diffuse glioma at designated medical institutions within the Beijing Tianzhu Comprehensive Bonded Zone.
Global First Dual IDH Inhibitor
Voranigo, the world’s first dual IDH inhibitor, marks the first innovative targeted therapy for IDH-mutant diffuse glioma in nearly two decades. Since its initial approval in the U.S. in August 2024, the drug has been approved in Canada, Australia, Israel, Switzerland, and the UAE. In November 2024, it became available at the Hainan Boao Lecheng Pilot Zone, marking its first use in Asia.
Beijing Approval and Policy Support
The approval in Beijing was facilitated through the “Green Channel for Clinically Urgent Imported Drugs and Medical Devices” and “Rare Disease Drug Security Pilot Zone.” These policies have significantly reduced patient wait times and ensured timely access to cutting-edge medical advancements. Under these initiatives, Beijing has approved 23 urgently needed imported drugs, including 20 rare disease treatments.
Availability in Leading Institutions
Voranigo is among the first batch of imported oncology drugs approved under this program and is now available at leading institutions, including Beijing Tiantan Hospital, Capital Medical University, and Peking Union Medical College Hospital.-Fineline Info & Tech